Abstract:During the past quarter century, the diagnosis and treatment of cystic fibrosis (CF) have been transformed by molecular sciences that initiated a new era with discovery of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene. The knowledge gained from that breakthrough has had dramatic clinical impact. Although once a diagnostic dilemma with long delays, preventable deaths, and irreversible pathology, CF can now be routinely diagnosed shortly after birth through newborn screening programs. This strategy of pre-symptomatic identification has eliminated the common diagnostic "odyssey" that was a failure of the healthcare delivery system causing psychologically traumatic experiences for parents. Therapeutic advances of many kinds have culminated in CFTR modulator treatment that can reduce the effects of or even correct the molecular defect in the chloride channel —the basic cause of CF. This astonishing advance has transformed CF care as described fully herein. Despite this impressive progress, there are challenges and controversies in the delivery of care. Issues include how best to achieve high sensitivity newborn screening with acceptable specificity; what course of action is appropriate for children who are identified through the unavoidable incidental findings of screening tests (CFSPID/CRMS cases and heterozygote carriers); how best to ensure genetic counseling; when to initiate the very expensive but life-saving CFTR modulator drugs; how to identify new CFTR modulator drugs for patients with non-responsive CFTR variants; how to adjust other therapeutic modalities; and how to best partner with primary care clinicians. Progress always brings new challenges, and this has been evident worldwide for CF. Consequently, this article summarizes the major advances of recent years along with controversies and describes their implications with an international perspective.

Emerging Approaches to Monitor and Modify Care in the Era of Cystic Fibrosis Transmembrane Conductance Regulators

Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy

New drugs, new challenges in cystic fibrosis care

The ageing of Cystic Fibrosis patients with new modulators: current gaps and challenges

Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis

Advances in Care and Outcomes for Children with Cystic Fibrosis

Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians

Unmet challenges in cystic fibrosis treatment with modulators

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis

Advances in the restoration of CFTR in children and pwCF with "mild disease"

Exploring perceptions of and decision‐making about CFTR modulators

The future of cystic fibrosis: A global perspective

Adapting the cystic fibrosis care model: Perspectives from people with CF, caregivers, and members of CF care teams

Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies

Implications for the Microbial Landscape in Cystic Fibrosis

Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis

Until it's done for everyone: the role of CFTR modulator label expansion

Attitudes toward and preparedness for lung transplantation among individuals with cystic fibrosis in the era of highly effective modulators

Future therapies for cystic fibrosis